Stability of Middle Molecule Clearance (EMIC2)

Klinik für Anästhesiologie

Status: Completed

Conditions: Continuous Hemodialysis

Treatments: Device: Hemodialysis with EMIC 2 filters

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01308073

EMIC2_2011_02_03

Details and patient eligibility

About

The investigators aim to show, whether all middle molecules are included in the clearance and whether this clearance is stable until 72 hours.

Full description

A better middle molecule clearance has been shown until 24 hours of duration. The investigators will extend our observations until 72 hours.

Enrollment: 15 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• informed consent
• age>18 years
• acute renal insufficiency with indication for continuous hemodialysis, according to RILFE classification F: serum creatinine increase > 3-fold or serum creatinine > 4mg/dl with acute increase of >0,5mg/dl Urine Output <0,3mg/kg/h for 24 h or anuria for 12 h
• body weight:60-80kg
• anticoagulation with citrate possible and indicated
• Dose for hemodialysis of 2l/h

Exclusion criteria

• participation in another clinical trial within on month prior to this study

• pregnancy or brest feeding

• septic shock

• interference with cystatin-C

  1. haemolysis <1g/dl
  2. Bilirubin<9mg/dl
  3. Triglyceride >700mg/dl
  4. rheumatoid factor > 300kIU/l

Trial design

15 participants in 1 patient group

EMIC 2 dialysis

Description:

Patients on ICU requiring dialysis for acute renal insufficiency

Treatment:

Device: Hemodialysis with EMIC 2 filters